Select a medication above to begin.
Combipatch
estradiol/ norethindrone acetate transdermal
Black Box Warnings .
Endometrial Cancer with Unopposed Estrogen in Patients with Intact Uterus
unopposed estrogen use incr. risk of endometrial CA in patients with intact uterus; adding progestogen has been shown to decr. risk of endometrial hyperplasia, a possible precursor to endometrial CA; perform adequate diagnostic measures (including directed or random endometrial sampling) to rule out malignancy in menopausal patient with abnormal genital bleeding of unknown etiology
Adult Dosing .
Dosage forms: PATCH: 0.05 mg/0.14 mg per day, 0.05 mg/0.25 mg per day
vasomotor symptoms, moderate-severe menopausal
- [apply 1 patch 2x/wk]
- Start: apply 0.05 mg/0.14 mg patch 2x/wk; Alt: apply estradiol transdermal 0.05 mg per day patch 2x/wk x2wk, then apply estradiol/norethindrone acetate transdermal patch 2x/wk x2wk, repeat; Info: use lowest effective estrogen dose, shortest effective tx duration
vulvovaginal atrophy, menopausal
- [apply 1 patch 2x/wk]
- Start: apply 0.05 mg/0.14 mg patch 2x/wk; Alt: apply estradiol transdermal 0.05 mg per day patch 2x/wk x2wk, then apply estradiol/norethindrone acetate transdermal patch 2x/wk x2wk, repeat; Info: use lowest effective estrogen dose, shortest effective tx duration; not preferred if local symptoms only
hypoestrogenism
- [apply 1 patch 2x/wk]
- Start: apply 0.05 mg/0.14 mg patch 2x/wk; Alt: apply estradiol transdermal 0.05 mg per day patch 2x/wk x2wk, then apply estradiol/norethindrone acetate transdermal patch 2x/wk x2wk, repeat; Info: for oopherectomy, hypogonadism, or primary ovarian failure
renal dosing
- [see below]
- renal disease: not defined, caution advised
- HD/PD: not defined, caution advised
hepatic dosing
- [see below]
- hepatic impairment/disease: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.